BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31552175)

  • 1. Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia.
    Wingelhofer B; Somervaille TCP
    Front Oncol; 2019; 9():850. PubMed ID: 31552175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.
    Gallipoli P; Giotopoulos G; Huntly BJ
    Ther Adv Hematol; 2015 Jun; 6(3):103-19. PubMed ID: 26137202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
    Kim TK; Gore SD; Zeidan AM
    Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia.
    Lu R; Wang GG
    Front Oncol; 2017; 7():241. PubMed ID: 29075615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
    Castelli G; Pelosi E; Testa U
    Onco Targets Ther; 2018; 11():131-155. PubMed ID: 29343972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
    Bewersdorf JP; Shallis R; Stahl M; Zeidan AM
    Ther Adv Hematol; 2019; 10():2040620718816698. PubMed ID: 30719265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours.
    Molica M; Perrone S
    Expert Rev Hematol; 2022 Nov; 15(11):973-986. PubMed ID: 36271671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
    Grieselhuber NR; Mims AS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.
    Sun Y; Chen BR; Deshpande A
    Front Oncol; 2018; 8():41. PubMed ID: 29527516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges.
    Green SD; Konig H
    Front Genet; 2020; 11():480. PubMed ID: 32536937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
    Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
    Magliulo D; Bernardi R; Messina S
    Front Oncol; 2018; 8():255. PubMed ID: 30073149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects.
    Gambacorta V; Gnani D; Vago L; Di Micco R
    Front Cell Dev Biol; 2019; 7():207. PubMed ID: 31681756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic alterations in acute myeloid leukemias.
    Mehdipour P; Santoro F; Minucci S
    FEBS J; 2015 May; 282(9):1786-800. PubMed ID: 25369368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disordered epigenetic regulation in MLL-related leukemia.
    Zhang Y; Chen A; Yan XM; Huang G
    Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in targeted therapy for acute myeloid leukemia.
    Yu J; Jiang PYZ; Sun H; Zhang X; Jiang Z; Li Y; Song Y
    Biomark Res; 2020; 8():17. PubMed ID: 32477567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapies for acute myeloid leukemia.
    Saygin C; Carraway HE
    J Hematol Oncol; 2017 Apr; 10(1):93. PubMed ID: 28420416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of epigenetic targets in acute myeloid leukemia.
    Verma S; Dhanda H; Singh A; Rishi B; Tanwar P; Chaudhry S; Siraj F; Misra A
    Am J Blood Res; 2021; 11(5):458-471. PubMed ID: 34824880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
    Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
    Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.